Cargando…
Eukaryotic Initiation Factor 2α - a Downstream Effector of Mammalian Target of Rapamycin - Modulates DNA Repair and Cancer Response to Treatment
In an effort to circumvent resistance to rapamycin – an mTOR inhibitor - we searched for novel rapamycin-downstream-targets that may be key players in the response of cancer cells to therapy. We found that rapamycin, at nM concentrations, increased phosphorylation of eukaryotic initiation factor (eI...
Autores principales: | Tuval-Kochen, Liron, Paglin, Shoshana, Keshet, Gilmor, Lerenthal, Yaniv, Nakar, Charles, Golani, Tamar, Toren, Amos, Yahalom, Joachim, Pfeffer, Raphael, Lawrence, Yaacov |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3808413/ https://www.ncbi.nlm.nih.gov/pubmed/24204783 http://dx.doi.org/10.1371/journal.pone.0077260 |
Ejemplares similares
-
MutT homolog 1 counteracts the effect of anti-neoplastic treatments in adult and pediatric glioblastoma cells
por: Versano, Ziv, et al.
Publicado: (2018) -
Overcoming Resistance of Cancer Cells to PARP-1 Inhibitors with Three Different Drug Combinations
por: Yalon, Michal, et al.
Publicado: (2016) -
Correction: Overcoming Resistance of Cancer Cells to PARP-1 Inhibitors with Three Different Drug Combinations
por: Yalon, Michal, et al.
Publicado: (2016) -
Pediatric glioblastoma cells are sensitive to drugs that inhibit eIF2α dephosphorylation and its phosphomimetic S51D variant
por: Eytan, Karin, et al.
Publicado: (2022) -
Primary care follow up of patients discharged from the emergency department: a retrospective study
por: Vinker, Shlomo, et al.
Publicado: (2004)